- Innovation Pharmaceuticals (OTCQB:IPIX) announces new data from ongoing lab testing of Brilacidin for COVID-19.
- In a human lung epithelial cell line, recently released data showed that Brilacidin reduced the coronavirus viral load by 95% and 97%, respectively, at two concentrations tested.
- The new results, based on the same assay method, demonstrated that a concentration 50% below the lower of the two previously tested concentrations of Brilacidin inhibited the coronavirus by ~90%.
- The company cites a Nature-published article that showed Gilead Sciences' (NASDAQ:GILD) remdesivir achieved 50% inhibition of SARS-CoV-2 in a time-of-addition experiment in animal cells.
- The data will be submitted for publication.
- A Phase 2 clinical trial should launch in Q4.